Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EquasensFRA:PHF 93 Receivables Turnover is 2.49 as of Dec. 2025. GuruFocus rates FRA:PHF with a GF Score™ of 93/100 and a GF Value™ of €90.29. The stock has 3 warning signs investors should review. Among 660 Healthcare Providers & Services companies, Equasens ranks worse than 73.03% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Equasens's Revenue for the
six
months ended in Dec. 2025 was €120.5 Mil. Equasens's average Accounts Receivable for the
six
months ended in Dec. 2025 was €48.5 Mil.
Hence, Equasens's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.49.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Equasens Receivables Turnover Related Terms
Equasens Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Equasens's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHF vs VEEV, BTSG, TEM: Receivables Turnover Comparison
For the Health Information Services subindustry, Equasens's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equasens Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Equasens's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Equasens's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equasens (FRA:PHF) has a Receivables Turnover of 2.49 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Equasens and its competitors. According to the industry distribution chart, Equasens ranks #482 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 73%.
Is Equasens' Receivables Turnover too high?
Equasens' current Receivables Turnover is 2.49. The Healthcare Providers & Services industry median Receivables Turnover is 7.75. Equasens' value of 2.49 is 67.9% below this industry median. Based on the distribution chart, Equasens ranks #482 out of 660 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Equasens has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Equasens' Receivables Turnover compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Equasens ranks #482 out of 660 companies for Receivables Turnover. This places Equasens in the lower half of its industry. The industry median Receivables Turnover is 7.75. Equasens' value of 2.49 is 67.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.75, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current Receivables Turnover of 2.49 is 67.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Equasens and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current Receivables Turnover is 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Equasens (FRA:PHF) has a current Receivables Turnover of 2.49. The stock's GF Value™ is €90.29, compared to a current price of €52.77 — trading 41.6% below its estimated fair value. The current Receivables Turnover is 2.49 and 67.9% below the Healthcare Providers & Services industry median of 7.75. Equasens' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Equasens (FRA:PHF), the current Receivables Turnover is 2.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Equasens (FRA:PHF) Overvalued in 2026?
Based on GuruFocus' analysis, Equasens stock appears to be undervalued.
The current stock price of €52.77 is trading 41.6% below its estimated GF Value™ of €90.29.
Key valuation signals for FRA:PHF:
Receivables Turnover: 2.49
GF Value™: €90.29 vs. price of €52.77 (41.6% below fair value)
Industry Position: 67.9% below the Healthcare Providers & Services median (#482 of 660)
No single metric tells the full story. See the FRA:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
93GF Score
Get the complete analysis for FRA:PHF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHF has been successfully added to your 
